{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:41:42Z","timestamp":1773232902348,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00502"],"award-info":[{"award-number":["PI20\/00502"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/01077"],"award-info":[{"award-number":["PI18\/01077"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00419"],"award-info":[{"award-number":["PI18\/00419"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00573"],"award-info":[{"award-number":["PI18\/00573"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,10,5]]},"DOI":"10.1038\/s41416-022-01886-4","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T19:02:49Z","timestamp":1655751769000},"page":"1142-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors"],"prefix":"10.1038","volume":"127","author":[{"given":"C.","family":"Barcel\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sis\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"de la Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Megino-Luque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1622-5311","authenticated-orcid":false,"given":"R.","family":"Navaridas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-4388","authenticated-orcid":false,"given":"O.","family":"Maiques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Urdanibia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Eritja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Potrony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Calbet-Llopart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-9745","authenticated-orcid":false,"given":"S.","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Mat\u00edas-Guiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6866-6114","authenticated-orcid":false,"given":"R. M.","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6038-178X","authenticated-orcid":false,"given":"A.","family":"Maci\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"1886_CR1","doi-asserted-by":"publisher","unstructured":"Kosmopoulou M, Giannopoulou AF, Iliou A, Benaki D, Panagiotakis A, Velentzas AD, et al. Human melanoma\u2010cell metabolic profiling: Identification of novel biomarkers indicating metastasis. Int J Mol Sci. 2020;21:2436.\u00a0https:\/\/doi.org\/10.3390\/ijms21072436.","DOI":"10.3390\/ijms21072436"},{"key":"1886_CR2","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00432-018-2726-1","volume":"144","author":"H Mishra","year":"2018","unstructured":"Mishra H, Mishra PK, Ekielski A, Jaggi M, Iqbal Z, Talegaonkar S. Melanoma treatment: from conventional to nanotechnology. J Cancer Res Clin Oncol. 2018;144:2283\u2013302.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1886_CR3","doi-asserted-by":"publisher","unstructured":"Trubini S, Ubiali A, Paties C, Cavanna L. Novel BRAF mutation in melanoma: a case report. Mol Clin Oncol. 2018;8:460\u20132. https:\/\/doi.org\/10.3892\/mco.2018.1555. Epub 2018 Jan 12.","DOI":"10.3892\/mco.2018.1555"},{"key":"1886_CR4","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.2147\/OTT.S182721","volume":"11","author":"S Kakadia","year":"2018","unstructured":"Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of us food and drug administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018;11:7095\u2013107.","journal-title":"Onco Targets Ther"},{"key":"1886_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/pcmr.12155","volume":"26","author":"A Das","year":"2013","unstructured":"Das A, Pushparaj C, Herreros J, Nager M, Vilella R, Portero M, et al. T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells. Pigment Cell Melanoma Res. 2013;26:874\u201385.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1886_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/pcmr.12690","volume":"31","author":"O Maiques","year":"2018","unstructured":"Maiques O, Barcel\u00f3 C, Panosa A, Pijuan J, Orgaz JL, Rodriguez-Hernandez I, et al. T-type calcium channels drive migration\/invasion in BRAFV600E melanoma cells through Snail1. Pigment Cell Melanoma Res. 2018;31:484\u201395.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1886_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-3701-5-1","volume":"5","author":"X Yang","year":"2015","unstructured":"Yang X, Yu DD, Yan F, Jing YY, Han ZP, Sun K, et al. The role of autophagy induced by tumor microenvironment in different cells and stages of cancer. Cell Biosci. 2015;5:1\u201311.","journal-title":"Cell Biosci"},{"key":"1886_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.8347.1","volume":"5","author":"A Ndoye","year":"2016","unstructured":"Ndoye A, Weeraratna AT. Autophagy\u2014an emerging target for melanoma therapy [version 1; referees: 2 approved]. F1000Research. 2016;5:1\u20139.","journal-title":"F1000Research"},{"issue":"Jun","key":"1886_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jid.2019.11.014","volume":"140","author":"C Barcel\u00f3","year":"2020","unstructured":"Barcel\u00f3 C, Sis\u00f3 P, Maiques O, Garc\u00eda-Mulero S, Sanz-Pamplona R, Navaridas R, et al. T-type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAFV600E melanoma. J Invest Dermatol. 2020;140:1253\u201365.","journal-title":"J Invest Dermatol"},{"key":"1886_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12020391","volume":"12","author":"C Barcel\u00f3","year":"2020","unstructured":"Barcel\u00f3 C, Sis\u00f3 P, Maiques O, de la Rosa I, Mart\u00ed RM, Maci\u00e0 A. T-type calcium channels: a potential novel target in melanoma. Cancers (Basel). 2020;12:1\u201313.","journal-title":"Cancers (Basel)"},{"key":"1886_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.01506","volume":"9","author":"L Di Leo","year":"2020","unstructured":"Di Leo L, Bodemeyer V, De, Zio D. The complex role of autophagy in melanoma evolution: new perspectives from mouse models. Front Oncol. 2020;9:1\u20139.","journal-title":"Front Oncol"},{"key":"1886_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7150\/jca.17648","volume":"8","author":"M Wang","year":"2017","unstructured":"Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8:761\u201373.","journal-title":"J Cancer"},{"key":"1886_CR13","doi-asserted-by":"publisher","unstructured":"Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5. https:\/\/doi.org\/10.1038\/s41392-020-00280-x.","DOI":"10.1038\/s41392-020-00280-x"},{"key":"1886_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16583-0","volume":"11","author":"S Di Blasio","year":"2020","unstructured":"Di Blasio S, van Wigcheren GF, Becker A, van Duffelen A, Gorris M, Verrijp K, et al. The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. Nat Commun. 2020;11:1\u201317. https:\/\/doi.org\/10.1038\/s41467-020-16583-0.","journal-title":"Nat Commun"},{"key":"1886_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17:302\u201317. https:\/\/doi.org\/10.1038\/nrc.2017.6.","journal-title":"Nat Rev Cancer"},{"key":"1886_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.semcdb.2017.06.021","volume":"78","author":"C Herraiz","year":"2018","unstructured":"Herraiz C, Jim\u00e9nez-Cervantes C, S\u00e1nchez-Laorden B, Garc\u00eda-Borr\u00f3n JC. Functional interplay between secreted ligands and receptors in melanoma. Semin Cell Dev Biol. 2018;78:73\u201384. https:\/\/doi.org\/10.1016\/j.semcdb.2017.06.021.","journal-title":"Semin Cell Dev Biol"},{"key":"1886_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","volume":"25","author":"F Klemm","year":"2015","unstructured":"Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198\u2013213.","journal-title":"Trends Cell Biol"},{"key":"1886_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature14336","volume":"520","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520:368\u201372.","journal-title":"Nature."},{"key":"1886_CR19","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.7150\/jca.21780","volume":"10","author":"BR da Cunha","year":"2019","unstructured":"da Cunha BR, Domingos C, Buzzo Stefanini AC, Henrique T, Polachini GM, Castelo-Branco P, et al. Cellular interactions in the tumor microenvironment: the role of secretome. J Cancer. 2019;10:4574\u201387.","journal-title":"J Cancer"},{"key":"1886_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.trecan.2020.02.020","volume":"6","author":"EC Madden","year":"2020","unstructured":"Madden EC, Gorman AM, Logue SE, Samali A. Tumour cell secretome in chemoresistance and tumour recurrence. Trends Cancer. 2020;6:489\u2013505. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.020.","journal-title":"Trends Cancer"},{"key":"1886_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2016.01.043.","journal-title":"Cancer Lett"},{"key":"1886_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood-2009-08-237412","volume":"115","author":"SJ Priceman","year":"2010","unstructured":"Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010;115:1461\u201371.","journal-title":"Blood."},{"key":"1886_CR23","doi-asserted-by":"publisher","first-page":"10635","DOI":"10.1007\/s13277-014-2627-0","volume":"35","author":"S Chockalingam","year":"2014","unstructured":"Chockalingam S, Ghosh SS. Macrophage colony-stimulating factor and cancer: a review. Tumor Biol. 2014;35:10635\u201344.","journal-title":"Tumor Biol"},{"key":"1886_CR24","doi-asserted-by":"publisher","unstructured":"Laoui D, van Overmeire E, de Baetselier P, van Ginderachter JA, Raes G. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front Immunol. 2014;5:489.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2014.00489.","DOI":"10.3389\/fimmu.2014.00489"},{"key":"1886_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aan3311","volume":"10","author":"NJ Neubert","year":"2018","unstructured":"Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Martignier C, Till\u00e9 L, et al. T cell\u2013induced CSF1 promotes melanoma resistance to PD1 blockade Natalie. Sci Transl Med. 2018;10:1\u201330.","journal-title":"Sci Transl Med"},{"key":"1886_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers9060068","volume":"9","author":"AR Dwyer","year":"2017","unstructured":"Dwyer AR, Greenland EL, Pixley FJ. Promotion of tumor invasion by tumor-associated macrophages: The role of CSF-1-activated phosphatidylinositol 3 kinase and Src family kinase motility signaling. Cancers (Basel). 2017;9:1\u201315.","journal-title":"Cancers (Basel)"},{"key":"1886_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-18796-8","volume":"8","author":"M Baghdadi","year":"2018","unstructured":"Baghdadi M, Endo H, Takano A, Ishikawa K, Kameda Y, Wada H, et al. High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Sci Rep. 2018;8:1\u201310. https:\/\/doi.org\/10.1038\/s41598-017-18796-8.","journal-title":"Sci Rep"},{"key":"1886_CR28","doi-asserted-by":"publisher","unstructured":"Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, et al. The RUNX1\/IL-34\/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight. 2018;3:e120422.\u00a0https:\/\/doi.org\/10.1172\/jci.insight.120422.","DOI":"10.1172\/jci.insight.120422"},{"key":"1886_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1377-8","volume":"15","author":"S Mok","year":"2015","unstructured":"Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, et al. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer. 2015;15:1\u201310.","journal-title":"BMC Cancer"},{"key":"1886_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jprot.2017.12.013","volume":"174","author":"T Liberato","year":"2018","unstructured":"Liberato T, Pessotti DS, Fukushima I, Kitano ES, Serrano SMT, Zelanis A. Signatures of protein expression revealed by secretome analyses of cancer associated fibroblasts and melanoma cell lines. J Proteom. 2018;174:1\u20138. https:\/\/doi.org\/10.1016\/j.jprot.2017.12.013.","journal-title":"J Proteom"},{"key":"1886_CR31","doi-asserted-by":"publisher","unstructured":"Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20:840.\u00a0https:\/\/doi.org\/10.3390\/ijms20040840.","DOI":"10.3390\/ijms20040840"},{"key":"1886_CR32","doi-asserted-by":"publisher","unstructured":"Pijuan J, Barcel\u00f3 C, Moreno DF, Maiques O, Sis\u00f3 P, Marti RM, et al. In vitro cell migration, invasion, and adhesion assays: From cell imaging to data analysis. Front Cell Dev Biol. 2019;7:107. https:\/\/doi.org\/10.3389\/fcell.2019.00107.","DOI":"10.3389\/fcell.2019.00107"},{"key":"1886_CR33","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/15548627.2016.1271512","volume":"13","author":"N Eritja","year":"2017","unstructured":"Eritja N, Chen BJ, Rodr\u00edguez-Barrueco R, Santacana M, Gatius S, Vidal A, et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy. 2017;13:608\u201324. https:\/\/doi.org\/10.1080\/15548627.2016.1271512.","journal-title":"Autophagy"},{"key":"1886_CR34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4161\/auto.4451","volume":"3","author":"S Kimura","year":"2007","unstructured":"Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3:452\u201360.","journal-title":"Autophagy"},{"key":"1886_CR35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/bjd.15121","volume":"176","author":"O Maiques","year":"2017","unstructured":"Maiques O, Maci\u00e0 A, Moreno S, Barcel\u00f3 C, Santacana M, Vea A, et al. Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma. Br J Dermatol. 2017;176:1247\u201358.","journal-title":"Br J Dermatol"},{"key":"1886_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:1\u20137.","journal-title":"Sci Rep"},{"key":"1886_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091\u20133. https:\/\/pubmed.ncbi.nlm.nih.gov\/19237447\/.","journal-title":"Bioinformatics."},{"issue":"Aug","key":"1886_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccr.2011.06.018","volume":"20","author":"V Sanz-Moreno","year":"2011","unstructured":"Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell. 2011;20(Aug):229\u201345. https:\/\/pubmed.ncbi.nlm.nih.gov\/21840487\/.","journal-title":"Cancer Cell."},{"key":"1886_CR39","doi-asserted-by":"publisher","unstructured":"Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 2018;10:eaan3311.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aan3311.","DOI":"10.1126\/scitranslmed.aan3311"},{"key":"1886_CR40","doi-asserted-by":"crossref","unstructured":"Dvo\u0159\u00e1nkov\u00e1 B, Szabo P, Kodet O, Strnad H, Kol\u00e1\u0159 M, Lacina L, et al. Intercellular crosstalk in human malignant melanoma. Vol. 254, Protoplasma. 2017;254:1143\u201350. https:\/\/pubmed.ncbi.nlm.nih.gov\/27807664\/.","DOI":"10.1007\/s00709-016-1038-z"},{"key":"1886_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"1886_CR42","first-page":"2687","volume":"41","author":"O Kodet","year":"2018","unstructured":"Kodet O, Dvo\u0159\u00e1nkov\u00e1 B, Bendlov\u00e1 B, S\u00fdkorov\u00e1 V, Krajsov\u00e1 I, \u0160tork J, et al. Microenvironment-driven resistance to B-Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts. Int J Mol Med. 2018;41:2687\u2013703.","journal-title":"Int J Mol Med"},{"key":"1886_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-0992-4","volume":"18","author":"Y Qu","year":"2019","unstructured":"Qu Y, Dou B, Tan H, Feng Y, Wang N, Wang D. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol Cancer. 2019;18:1\u201316.","journal-title":"Mol Cancer"},{"key":"1886_CR44","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1172\/JCI43490","volume":"120","author":"D Chinnasamy","year":"2010","unstructured":"Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RRK, Morgan RA, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010;120:3953\u201368.","journal-title":"J Clin Invest"},{"key":"1886_CR45","doi-asserted-by":"publisher","unstructured":"Landskron G, De La Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.\u00a0https:\/\/doi.org\/10.1155\/2014\/149185. Epub 2014 May 13.","DOI":"10.1155\/2014\/149185"},{"key":"1886_CR46","first-page":"267","volume":"21","author":"DR Bielenberg","year":"2015","unstructured":"Bielenberg DR, Zetter BR. The contribution of angiogenesis to the process of metastasis. Cancer J (U S). 2015;21:267\u201373.","journal-title":"Cancer J (U S)"},{"issue":"May","key":"1886_CR47","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1084\/jem.20081605","volume":"206","author":"Y Kubota","year":"2009","unstructured":"Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009;206(May):1089\u2013102. https:\/\/pubmed.ncbi.nlm.nih.gov\/19398755\/.","journal-title":"J Exp Med"},{"key":"1886_CR48","doi-asserted-by":"crossref","unstructured":"Fend L, Accart N, Kintz J, Cochin S, Reymann C, Le Pogam F, et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS ONE. 2013. https:\/\/pubmed.ncbi.nlm.nih.gov\/24019914\/.","DOI":"10.1371\/journal.pone.0073310"},{"key":"1886_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, R\u00fcttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5:1\u201313.","journal-title":"J Immunother Cancer"},{"key":"1886_CR50","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl J Med. 2011;364:2507\u201316.","journal-title":"N. Engl J Med"},{"key":"1886_CR51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508:118\u201322. https:\/\/doi.org\/10.1038\/nature13121.","journal-title":"Nature"},{"key":"1886_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1089381","volume":"5","author":"SF Ngiow","year":"2016","unstructured":"Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Bosenberg M, et al. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600Emelanoma. Oncoimmunology. 2016;5:1\u201311. https:\/\/doi.org\/10.1080\/2162402X.2015.1089381.","journal-title":"Oncoimmunology"},{"key":"1886_CR53","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","volume":"86","author":"G Solinas","year":"2009","unstructured":"Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065\u201373.","journal-title":"J Leukoc Biol"},{"key":"1886_CR54","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"B-Z Qian","year":"2010","unstructured":"Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:1477\u201390.","journal-title":"Cell"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01886-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01886-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01886-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T23:06:33Z","timestamp":1663110393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01886-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,10,5]]}},"alternative-id":["1886"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01886-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experimental committee approved animal work procedures (CEEA from University of Lleida). The Clinical Research Ethics Committee of the HCB (study registry 2013\/8305) approved this study and each study participant signed written informed consent in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}